Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2016

View Archived Issues

New collaboration to focus on GPCR targets for cancer immunotherapy

New mutations in known disease-associated genes

BERG enters CRADA with partners of DDCBCP

S-63845 is a highly potent and selective MCL1 inhibitor with efficacy in cancer models

Selective phosphorylation of Rb by p38 prevents proliferation in cancer cells

Alphamab starts phase I trial of KN-015

OneStep-1 and OneStep-2 phase III trials do not meet primary clinical endpoint

Nordic Nanovector and Heidelberg Pharma collaborate on ADCs for leukemia

Oasmia Pharmaceutical acquires Karo Pharma's KB-9520

Heat Biologics forms new subsidiary, Zolovax

[18F]PF-06684511 as a novel BACE-selective radioligand for PET imaging

Anacor Pharmaceuticals patents antiprotozoal agents

AstraZeneca reports promising findings from phase III SOLO-2 trial of Lynparza in ovarian cancer

Lewis and Clark Pharmaceuticals discloses A2B receptor antagonists

Active Biotech grants NeoTX exclusive rights to develop and commercialize Anyara for cancer

Horizon Pharma completes acquisition of Raptor Pharmaceutical

Auspex Pharmaceuticals describes S1P1 receptor modulators

Gilead Sciences develops HIV integrase inhibitors

Propanc Health Group completes toxicokinetic study of PRP

CureDuchenne announces launch of cTAP consortium

OncoGenex reports survival results from phase II trial of apatorsen in metastatic bladder cancer

Portola Pharmaceuticals submits NDA to FDA for betrixaban

FDA grants fast track designation to ABO-102 for MPS IIIA

AmpliPhi Biosciences reports topline results from phase I trial of AB-SA01

Fimbrion Therapeutics to collaborate with GSK to develop UTI-preventing drug

New variant in SERPINC1 may be a disease-causing mutation for antithrombin-III type I deficiency

Scynexis completes additional studies of SCY-078

Harvard College presents antibacterial agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...